eXciteOSA® Daytime Sleep Apnea Therapy Now Covered by Georgia Medicaid Signifier Medical Technologies Limited (“Signifier”), a global leader in sleep-disordered breathing treatments, announced today that its non-invasive daytime therapy, eXciteOSA®, is now covered under Georgia Medicaid policy 1320. This development…
Seaport Therapeutics Publishes Research on 55% Drug Absorption via Lymphatics with Glyph™ Platform Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines, has announced the publication of new research highlighting the unique capabilities of its Glyph™ platform…
First Large-Scale Study Links Nasal Anatomy to Allergy Symptoms at Key Conference A pioneering study presented at the Western Allergy Conference 2025 is the first large-scale investigation to explore the impact of nasal anatomy on upper airway allergies, utilizing real-world…
New Interactive Storybook Educates Children on Rare Kidney Disease Through Adventure Alexion, AstraZeneca Rare Disease has introduced a new electronic storybook designed to help children living with atypical Haemolytic Uraemic Syndrome (aHUS), a rare kidney disease. The interactive book aims…
GenSight Biologics Reveals 5-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy from REFLECT Study GenSight Biologics, a biopharma company dedicated to developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released the final efficacy and…
Charles River and Deciphex Expand Partnership to Enhance Digital Pathology with Exclusive Image Management Solutions Charles River Laboratories (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, have announced the next phase of their strategic collaboration. The focus will…
Ellipses Licenses First-in-Class Novel Immuno-Oncology Agent Ellipses Pharma Limited (“Ellipses”), a global drug development company dedicated to advancing cancer treatments, announced today that it has in-licensed the global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody targeting CNTN4, a recently…
RenovoRx Closes $12.1 Million Public Offering of Common Stock RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies, has successfully closed its previously announced $12.1 million underwritten public offering of common stock. The offering, which…
Particle Health Earns Certification for Surescripts Medication History for Populations Particle Health, a leading intelligent data platform that aggregates and delivers actionable patient insights to healthcare organizations, has announced the successful completion of its certification for Surescripts Medication History for…
Glox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced the appointment of Dr. Michael Murray as Chair of…
Owens & Minor Launches ByramConnect Digital Platform for Chronic Health Conditions Byram Healthcare, a leader in home-based care and a part of Owens & Minor (NYSE: OMI), has recently introduced ByramConnect™, a personalized digital health program powered by the Welldoc…
Silobreaker Partners with Health-ISAC to Offer Free Trial of Threat Intelligence Platform Silobreaker, a leading security and threat intelligence technology company, has announced a new partnership with the Health Information Sharing and Analysis Center (Health-ISAC) as a Community Services Partner.…